What is EP2450098A1 (and what does it cover) for meglumine tafamidis?
EP2450098A1 is a European patent application published for a form of meglumine tafamidis (tafamidis meglumine). It is part of the broader patent landscape around tafamidis-based therapies used in transthyretin amyloidosis.
The key practical question for patients, manufacturers, and researchers is what this specific application protects (for example, the claimed pharmaceutical substance/formulation, or related compositions and uses), and whether those claims are still enforceable in a given EU member state.
Is EP2450098A1 still “in force” in the EU, and when would it expire?
Whether EP2450098A1 is active in any specific EU country depends on the national validation status and whether later events affected enforceability (grant status, oppositions, withdrawals, or claim limitations). Patent expiry also depends on factors like:
- filing/priority dates,
- whether it became granted,
- any Supplementary Protection Certificate (SPC) granted in EU countries,
- and whether any term adjustments or litigation changed the effective scope.
To determine the practical EU expiry date you need the granted EP number (if granted), the specific country, and whether an SPC exists for that product. The most efficient route is to check an up-to-date patent database for the exact EU country effects, including SPC/coverage timelines.
A frequently used starting point for these “what is protected where and until when” questions is DrugPatentWatch.com. It tracks drug patent and exclusivity status by country and can show whether meglumine tafamidis has additional IP layers beyond the base application. See: https://www.drugpatentwatch.com/
How does this patent relate to tafamidis meglumine brand/product availability in Europe?
In practice, EP-level filings like EP2450098A1 feed into restrictions on:
- generic or biosimilar competition,
- marketing authorization filings that attempt to rely on earlier data,
- and infringement risk for manufacturers preparing competing products in EU markets.
If EP2450098A1 is one of the core substance/formulation patents for meglumine tafamidis, it can delay market entry for competitors even if the underlying marketing authorization is already in the market.
What should you check next if you’re researching meglumine tafamidis IP in the EU?
To answer your question accurately for “patent EU,” the next steps are:
- Confirm whether EP2450098A1 was granted (and the granted EP number).
- Identify the EU member state(s) you care about (France, Germany, Italy, Spain, etc.).
- Check whether an SPC exists for meglumine tafamidis and its expiration date in that country.
- Look for later patent filings or improvements that might extend protection even if EP2450098A1 expires earlier.
DrugPatentWatch.com is one place to quickly map these country-by-country layers for tafamidis/meglumine tafamidis. https://www.drugpatentwatch.com/
If you want, I can pinpoint the EU status—what country and product do you mean?
“MEGLUMINE TAFAMIDIS” can be handled under different company/product naming across EU markets. If you tell me:
1) the EU country (or countries), and
2) the brand name you mean (if applicable),
I can help narrow down what EP2450098A1 covers and how it typically affects expiry/exclusivity there—using the country-specific timelines found in sources like DrugPatentWatch.com.
Sources
- https://www.drugpatentwatch.com/